Form 8-K - Current report:
SEC Accession No. 0001558370-23-000493
Filing Date
2023-01-25
Accepted
2023-01-25 08:05:48
Documents
14
Period of Report
2023-01-23
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aytu-20230123x8k.htm   iXBRL 8-K 36999
2 EX-99.1 aytu-20230123xex99d1.htm EX-99.1 11571
3 GRAPHIC aytu-20230123xex99d1001.jpg GRAPHIC 6019
  Complete submission text file 0001558370-23-000493.txt   180467

Data Files

Seq Description Document Type Size
4 EX-101.SCH aytu-20230123.xsd EX-101.SCH 3129
5 EX-101.LAB aytu-20230123_lab.xml EX-101.LAB 15901
6 EX-101.PRE aytu-20230123_pre.xml EX-101.PRE 10058
8 EXTRACTED XBRL INSTANCE DOCUMENT aytu-20230123x8k_htm.xml XML 4866
Mailing Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112
Business Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

IRS No.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 23549864
SIC: 2834 Pharmaceutical Preparations